Kamada’s (KMDA) “Buy” Rating Reiterated at HC Wainwright

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 50.27% from the company’s previous close.

Kamada Trading Up 7.6 %

NASDAQ:KMDA opened at $7.32 on Friday. The stock’s 50-day moving average is $6.06 and its 200-day moving average is $5.67. Kamada has a 1-year low of $4.74 and a 1-year high of $7.96. The stock has a market cap of $420.75 million, a P/E ratio of 26.14 and a beta of 0.98.

Hedge Funds Weigh In On Kamada

An institutional investor recently bought a new position in Kamada stock. Plato Investment Management Ltd acquired a new stake in Kamada Ltd. (NASDAQ:KMDA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.